Benzinga | Apr 29, 2021 04:21PM EDT

Biomarin Pharmaceutical Q1 GAAP EPS $0.09 Beats $(0.10) Estimate, Sales $486.00M Beat $446.45M Estimate; Reaffirms FY21 Guidance'

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.10) by 190 percent. This is a 79.55 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $486.00 million which beat the analyst consensus estimate of $446.45 million by 8.86 percent. This is a 3.20 percent decrease over sales of $502.07 million the same period last year.